Ask about this productRelated genes to: ZRSR2 antibody
- Gene:
- ZRSR2 NIH gene
- Name:
- zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2
- Previous symbol:
- U2AF1L2
- Synonyms:
- U2AF1-RS2, URP, ZC3H22
- Chromosome:
- Xp22.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-24
- Date modifiied:
- 2019-04-23
Related products to: ZRSR2 antibody
Related articles to: ZRSR2 antibody
- To explore the clinical characteristics and prognostic significance of myelodysplastic neoplasms (MDS) with biallelic TET2 inactivation (bi-TET2) . Clinical data from 1 730 newly diagnosed MDS patients treated at Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College between August 2016 and June 2025, with next-generation sequencing data, were retrospectively collected. The clinical characteristics and prognosis of patients with biallelic TET2 inactivation were analyzed. Thirty-nine patients (2.3% ) harbored bi-TET2, including two with copy-neutral loss of heterozygosity on chromosome 4q24. Compared with patients with monoallelic TET2 mutations (=147) and those without TET2 mutations (=1 544), patients with bi-TET2 carried more gene mutations overall [4 (: 3, 6) 4 (: 2, 5) 2 (: 1, 4), <0.001] and had higher frequencies of mutations in ASXL1 (38.5% 29.9% 20.5%, =0.001), SRSF2 (28.2% 12.9% 4.5%, <0.001), SF3B1 (25.6% 18.4% 11.7%, =0.004), EZH2 (18.0% 7.5% 4.5%, =0.002), CUX1 (12.8% 3.4% 1.4%, <0.001), KRAS (10.3% 4.3% 2.1%, =0.006), CBL (10.3% 3.4% 2.6%, =0.030), ZRSR2 (10.3% 6.1% 3.2%, =0.017), and CEBPA (7.7% 1.4% 1.2%, =0.019). Patients with bi-TET2 were older at diagnosis [65 (: 58, 69) 61 (: 50, 67) 55 (: 44, 64) years, <0.001] and had a higher proportion of normal karyotype (69.2% 46.3% 44.8%, =0.024). Patients with bi-TET2 had a significantly shorter median overall survival (OS) time than patients with monoallelic TET2 mutations and those without TET2 mutations [18.5 (95% : 13.1-25.0) 40.6 (95% : 22.8-60.9) 54.7 (95% : 47.1-69.4) months, =0.009]. Stratified analysis by IPSS-M prognostic risk categories showed that, in the high-risk group (moderate high-risk, high-risk, and very high-risk), patients with bi-TET2 had a significantly shorter median OS time[12.4 (95% : 8.4-NA) months] than patients with monoallelic TET2 mutations [19.7 (95% : 14.9-39.9) months] and those without TET2 mutations [32.0 (95% : 27.6-37.4) months, <0.001]. In contrast, no significant difference in OS was observed in the low-risk group (very low-risk, low-risk, and moderate low-risk) . Patients with MDS harboring biallelic TET2 inactivation exhibit distinct clinical and molecular characteristics and in patients with relatively high IPSS-M risk, their prognosis is worse than that of patients with monoallelic TET2 mutations. - Source: PubMed
Wang XLiu L LLi BJia Y JLi C WQin T JXu Z FQu S QPan L JGao Q YJiao MXiao Z J - Cabazitaxel is a second-generation semisynthetic taxane approved for the treatment of prostate cancer. Vitamin K, an essential nutrient involved in blood coagulation and bone metabolism, has also been shown to have antineoplastic effects. However, no information is currently available regarding the combinatorial effects of cabazitaxel and menadione (VK3, a derivative of vitamin K) on prostate cancer cells. Therefore, we investigated the in vitro effects of cabazitaxel, VK3, and their combination on growth, mitochondrial bioenergetics, and glycolytic parameters using the human prostate cancer cell lines PC-3 and DU 145. All treatments inhibited the cell growth, but the combination of cabazitaxel and VK3 produced a synergistic effect that was stronger than either compound alone, and these effects were accompanied by cell line-specific bioenergetic changes and glycolytic responses. Furthermore, high-throughput transcriptomic profiling of PC-3 cells revealed distinct sets of differentially expressed genes for each treatment, with the greatest effect established by the combinatorial treatment, followed by VK3, and then cabazitaxel. Gene ontology analyses showed that the combinatorial treatment was associated with biological processes such as positive regulation of reactive oxygen species metabolic process, steroid metabolic process, proteolysis, and signal transduction. Notably, the treatments altered the gene expression of several tumorigenic and immunologic mediators, including , , , , and , which may impact cancer cell behavior. In conclusion, these in vitro findings indicate that the combination of cabazitaxel with VK3 is more effective in inhibiting prostate cancer cell growth than either agent alone and provide exploratory mechanistic insight into their effects on cancer cell metabolism and gene expression. - Source: PubMed
Publication date: 2026/05/17
Gómez-Rosas Ana LauraChirinos MayelNoyola-Martínez NancySegovia-Mendoza MarianaTorres-Ramírez NayeliRomero-Córdoba SandraNoriega Lilia GGarcía-Olivares MitziLarrea FernandoBarrera David - The loss of chromosome Y (LOY) in leukocytes is the most prevalent form of clonal mosaicism observed in older men. Previous studies provided multiple pieces of evidence for the effect of LOY on the immune system and connected LOY to elevated risk of all major causes of mortality, including cardiovascular diseases and cancer. Despite these associations, the dynamic effects of LOY across the developmental trajectories of immune cell populations remain unclear. We utilized single-cell RNA-sequencing data from the peripheral blood mononuclear cells of 416 male donors (median age = 68) from the OneK1K cohort. LOY was identified in 45,304 cells (8.76%) and exhibited cell type-specific effects on immune cells along the differentiation trajectories. The largest frequency was detected in monocytes (18.6% in classical and 17.1% in nonclassical) with a progressive decrease along the transition trajectory from 22.6% to 15.8% (p = 2.00 × 10), and a gradual reduction in the expression of nonclassical markers LYPD2 and C1QA. LOY is associated with a profibrotic signature in classical monocytes marked by downregulation of IL1B (log FC = -0.22, p = 2.84 × 10) and MYC-regulated genes (log FC = -0.25, p = 2.22 × 10), consistent with previous observations that LOY-associated macrophages are polarized toward a fibrotic rather than inflammatory phenotype in cardiac and pulmonary injury. Notably, we detected aberrant expression of XIST, the essential X-chromosome-inactivation lncRNA that is not normally expressed in males, and upregulation of genes known to escape X-inactivation, including male-biased cancer-related genes KDM6A, DDX3X, KDM5C, and ZRSR2. Our results indicate associations between LOY and cell type-specific transcriptional changes, including aberrant X-inactivation features. - Source: PubMed
Dawoud AhmedGreen LukeRackham Owen - The 2022 European Leukemia Net (ELN) risk stratification categorizes acute myeloid leukemia (AML) with myelodysplasia-related gene (MRG) mutations - including , , , , , , , and/or - as "adverse-risk". However, the prognostic relevance of MRG mutations in patients with favorable-risk AML remains uncertain. - Source: PubMed
Publication date: 2026/03/09
Zhang LuluYing ShuangweiFang FangLi QianAn FurunLi JingwenSun JieZheng WeiyanZhai ZhiminZhu Yuanyuan - NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) is generally classified as favorable-risk under the 2022 European LeukemiaNet (ELN-2022) guidelines, except in the presence of FLT3-internal tandem duplication or adverse-risk cytogenetics. However, the prognostic significance of co-occurring myelodysplasia-related gene (MRG) mutations remains unclear, with prior studies yielding inconsistent results. To clarify this issue, we conducted a systematic review and meta-analysis in accordance with PRISMA guidelines, searching PubMed, Embase, and MEDLINE through March 2025. MRG mutations were defined as pathogenic variants in ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 and RUNX1, and the primary analysis incorporated studies regardless of RUNX1 inclusion. Data from ten cohorts across nine studies (one of which included an independent validation cohort), encompassing a total of 4,363 patients, were analyzed. Of these, 655 patients (15.0%) harbored co-occurring MRG mutations. Among the patients with ELN-2022 intermediate risk (n=1,294), 108 (8.3%) had MRG mutations. The presence of MRG mutations was significantly associated with inferior overall survival (pooled hazard ratio [HR] 1.30; 95% confidence interval [CI], 1.11-1.51; p. - Source: PubMed
Publication date: 2026/02/26
Chang Yu-SungLee Yi-WeiLiu Chieh-YuOthman JadEckardt Jan-NiklasZhou QianghuaTien Feng-MingLyu Ting-WeiTsai Xavier Cheng-HongLin Chien-ChinChang HongKo Bor-ShengChou Wen-ChienRöllig ChristophRussell NigelDillon RichardHou Hsin-An